Interferon beta‐1a vs placebo
Change in grip strength · people with inclusion body myositis
1 finding from 1 review
- no estimate extracted2 studies · 58 participantsGRADE not reported
Findings
What do systematic reviews say?
140 questions · 146 findings · 18 reviews
No studies found 32 · 21.9%GRADE not reported 16 · 11%Very low 23 · 15.8%Low 51 · 34.9%Moderate 24 · 16.4%High 0 · 0%
Interferon beta‐1a vs placebo
Change in timed walk at 6 months (%) e.g. 10‐metre or 6‐minute walk test at 6 months ‐ not measured · people with inclusion body myositis
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Interferon beta‐1a vs placebo
Significant adverse events · people with inclusion body myositis
1 finding from 1 review
- no estimate extracted2 studies · 58 participantsGRADE not reported
Interferon beta‐1a vs placebo
Muscle strength · people with inclusion body myositis
2 findings from 1 review
- no estimate extracted2 studies · 58 participantsModerate
- no estimate extractedStudies not reportedNo studies found
Interferon beta‐1a vs placebo
Change in muscle mass at 6 months (%) ‐ not measured · people with inclusion body myositis
1 finding from 1 review
- no estimate extracted2 studies · 58 participantsModerate
Standard interferon plus ribavirin vs standard interferon
Death · patients on HD with HCV infection
The review found no eligible studies for this question.
1 finding from 1 review
- Interventions for dialysis patients with hepatitis C virus (HCV) infection 2023 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
Standard interferon plus ribavirin vs standard interferon
Relapse Number of participants having recurrence after stopping · patients on HD with HCV infection
The review found no eligible studies for this question.
1 finding from 1 review
- Interventions for dialysis patients with hepatitis C virus (HCV) infection 2023 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
Standard interferon plus ribavirin vs standard interferon
End‐of‐treatment response · patients on HD with HCV infection
The review found no eligible studies for this question.
1 finding from 1 review
- Interventions for dialysis patients with hepatitis C virus (HCV) infection 2023 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
Standard interferon plus ribavirin vs standard interferon
Sustained virological response · patients on HD with HCV infection
The review found no eligible studies for this question.
1 finding from 1 review
- Interventions for dialysis patients with hepatitis C virus (HCV) infection 2023 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
Standard interferon plus ribavirin vs standard interferon
Treatment discontinuation · patients on HD with HCV infection
Standard interferon plus ribavirin may leads to higher treatment discontinuation compared with standard interferon alone (low certainty).
1 finding from 1 review
- Interventions for dialysis patients with hepatitis C virus (HCV) infection 2023 · Cochrane Headline outcomes onlyRR 2.97 [1.19, 7.36]1 study · 52 participantsLow
Standard interferon plus ribavirin vs standard interferon
Adverse events · patients on HD with HCV infection
The review found no eligible studies for this question.
1 finding from 1 review
- Interventions for dialysis patients with hepatitis C virus (HCV) infection 2023 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
Pegylated interferon plus ribavirin vs pegylated interferon alone
Death · patients on HD with HCV infection
The review found no eligible studies for this question.
1 finding from 1 review
- Interventions for dialysis patients with hepatitis C virus (HCV) infection 2023 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
Pegylated interferon plus ribavirin vs pegylated interferon alone
Relapse Number of participants having recurrence after stopping · patients on HD with HCV infection
Pegylated interferon plus ribavirin may leads to lower relapse(recurrence after stopping) compared with pegylated interferon alone (low certainty).
1 finding from 1 review
- Interventions for dialysis patients with hepatitis C virus (HCV) infection 2023 · Cochrane Headline outcomes onlyRR 0.33 [0.23, 0.48]1 study · 377 participantsLow
Pegylated interferon plus ribavirin vs pegylated interferon alone
End‐of‐treatment response · patients on HD with HCV infection
Pegylated interferon plus ribavirin showed no clear difference in end‐of‐treatment response compared with pegylated interferon alone (low certainty).
1 finding from 1 review
- Interventions for dialysis patients with hepatitis C virus (HCV) infection 2023 · Cochrane Headline outcomes onlyRR 1.01 [0.94, 1.09]1 study · 377 participantsLow
Pegylated interferon plus ribavirin vs pegylated interferon alone
Sustained virological response · patients on HD with HCV infection
Pegylated interferon plus ribavirin may leads to higher sustained virological response compared with pegylated interferon alone (low certainty).
1 finding from 1 review
- Interventions for dialysis patients with hepatitis C virus (HCV) infection 2023 · Cochrane Headline outcomes onlyRR 1.8 [1.46, 2.21]1 study · 377 participantsLow
Pegylated interferon plus ribavirin vs pegylated interferon alone
Treatment discontinuation · patients on HD with HCV infection
Pegylated interferon plus ribavirin showed no clear difference in treatment discontinuation compared with pegylated interferon alone (low certainty).
1 finding from 1 review
- Interventions for dialysis patients with hepatitis C virus (HCV) infection 2023 · Cochrane Headline outcomes onlyRR 1.71 [0.69, 4.24]1 study · 377 participantsLow
Pegylated interferon plus ribavirin vs pegylated interferon alone
Adverse events · patients on HD with HCV infection
Pegylated interferon plus ribavirin may leads to higher adverse events compared with pegylated interferon alone (low certainty).
1 finding from 1 review
- Interventions for dialysis patients with hepatitis C virus (HCV) infection 2023 · Cochrane Headline outcomes onlyRR 1.1 [1.01, 1.19]1 study · 377 participantsLow
Standard interferon vs placebo or control
Death · patients on HD with HCV infection
Standard interferon showed no clear difference in death compared with placebo or control (low certainty).
1 finding from 1 review
- Interventions for dialysis patients with hepatitis C virus (HCV) infection 2023 · Cochrane Headline outcomes onlyRR 0.89 [0.06, 13.23]5 studies · 134 participantsLow
Standard interferon vs placebo or control
Relapse Number of participants having recurrence after stopping · patients on HD with HCV infection
Standard interferon showed no clear difference in relapse(recurrence after stopping intervention) compared with placebo or control (low certainty).
1 finding from 1 review
- Interventions for dialysis patients with hepatitis C virus (HCV) infection 2023 · Cochrane Headline outcomes onlyRR 0.72 [0.28, 1.88]1 study · 12 participantsLow
Standard interferon vs placebo or control
End‐of‐treatment response · patients on HD with HCV infection
Standard interferon probably leads to higher end‐of‐treatment response compared with placebo or control (moderate certainty).
1 finding from 1 review
- Interventions for dialysis patients with hepatitis C virus (HCV) infection 2023 · Cochrane Headline outcomes onlyRR 8.62 [3.03, 24.55]5 studies · 132 participantsModerate